Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HN2301 in refractory myasthenia gravis
NCT06965309Terminated
- Sponsor
- Shenzhen MagicRNA Biotechnology
- Start
- Jan 2026
- Primary completion
- Feb 2026
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of HN-2301 in myasthenia gravis (MG), sponsored by Shenzhen MagicRNA Biotechnology. Primary endpoint: Adverse events related to HN2301 at 3 months. Started Jan 2026; status: terminated.
02
Drugs
HN-2301
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06965309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06965309.